AVANTI - Avelox® in Acute Exacerbations of chroNic bronchiTIs

Bayer

Status: Completed

Conditions: Bronchitis, Chronic

Treatments: Drug: Moxifloxacin (Avelox, BAY12-8039)

Study type: Observational

Funder types: Industry

Identifiers

NCT00846911

13857 (Other Identifier)

14689

14009 (Other Identifier)

14008 (Other Identifier)

13856 (Other Identifier)

13855 (Other Identifier)

14007 (Other Identifier)

AX0701 (Other Identifier)

13598 (Other Identifier)

Details and patient eligibility

About

The objective of this global non-interventional study is to evaluate the impact of Acute Exacerbation of Chronic Bronchitis(AECB) on the patient and the community as well as the safety and effect of a treatment with Moxifloxacin tablets in daily life clinical practice. This includes data on the course of symptom relief, speed of return to normal daily life activities as well as records on adverse events.

This study will be performed in accordance with international guidelines like EMEA (EMEA, EUDRALEX Volume 9A, Pharmacovigilance for Medicinal Products for Human Use) as well as local laws.

Enrollment: 2,672 patients

Sex: All

Ages: 35+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients at least 35 years of age with a diagnosis of Acute Exacerbation of Chronic Bronchitis (AECB) and decision taken by the investigator to treat with Avelox.

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information.

Trial design

2,672 participants in 1 patient group

Group 1

Treatment:

Drug: Moxifloxacin (Avelox, BAY12-8039)